Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
about
Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent mannerLaminin-binding integrin gene copy number alterations in distinct epithelial-type cancersCabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian CentreSelf-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery systemPreclinical profile of cabazitaxel.Evolving Personalized Therapy for Castration-Resistant Prostate Cancer.Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following ChemotherapyCastration-resistant prostate cancer: mechanisms, targets, and treatment.Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4Management of metastatic castration-resistant prostate cancerPhase II Study of Pomalidomide in Patients with Castration-Resistant Prostate CancerThe unfolding treatment landscape for men with castration-resistant prostate cancer.Cytoskeleton targeting value in prostate cancer treatment.Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate CancerMicroRNA-181a promotes docetaxel resistance in prostate cancer cells.Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.Mechanisms of Therapeutic Resistance in Prostate Cancer.Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.Texas Native Plants Yield Compounds with Cytotoxic Activities against Prostate Cancer Cells.ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain.Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.New therapeutics to treat castrate-resistant prostate cancer.Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis.Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancerEvolution of In Silico Strategies for Protein-Protein Interaction Drug DiscoveryImproving adenoviral vectors and strategies for prostate cancer gene therapy
P2860
Q28537723-4FFCDDF8-727C-47E9-8DE2-95A69D24BF8AQ30489312-3C2AFF29-9CF5-49FE-9848-8A4136BCF93CQ31135810-73974D54-36ED-4975-8CD8-64655365D7ACQ33633314-09CF9FB4-91EB-4369-B17F-ADFDE30E3DA5Q34394251-DE1F19F1-80B1-4E59-812E-DF2192482611Q34691562-BB4259E6-4C4A-4D9C-9C0C-D80F6A339FC8Q35216973-5DF275AF-7DC8-4EAA-AEFA-8F9D87987006Q35864027-E356457A-1993-4946-8489-B1F2463380E9Q36059621-D0F01ACE-7615-495B-88DD-F285B70174CBQ36936267-1CF797E0-5842-43BD-82E2-6334EA8F0EC0Q37137426-4CDE29DE-EB65-45DF-A133-FECE408E3CCCQ38056914-A29BD094-D858-4361-B3A7-1ECE7542436BQ38265569-AF7B2361-9C3B-4812-9E45-09221F7300A0Q38361928-F04247F4-9DBF-4846-8409-54D58D9360B2Q38639852-2968FD52-BBD0-432D-B708-CAB995167C12Q38704252-4C8845A4-D4A3-4AEA-A581-59F0B73FC743Q38739235-449C7D1F-8B62-4196-9124-C232AEF1AB14Q38754316-28DEF4C8-3259-45D0-A883-690ADB81D855Q40622027-36E06F7B-1948-4770-9EEF-B721B814B865Q41186415-58C893F4-02A0-4376-A8C0-F0B57B407B52Q46495734-66C707BF-68ED-44BA-AB80-3474F6E22202Q50504158-A4B45574-F318-4C41-956E-98B16A80A852Q50642716-A856112E-20AC-493E-B14D-E30B0308A149Q52602328-C97320FB-FA88-48F1-85BC-E2F8DE3BB29BQ52641603-BB24C580-63CC-41D6-ADCE-97982C20EC8EQ55364968-FC729C08-F2C7-4339-BFE4-6285BFE4EAFAQ58542923-7A18823C-6947-4349-BB4C-8A031912C6D8Q58697064-027C9912-C6FC-40DB-AC60-B6A760DF3CC5Q58801177-ECC7C283-2D41-4AE7-BC4A-06F27986CEBC
P2860
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@ast
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@en
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@nl
type
label
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@ast
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@en
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@nl
prefLabel
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@ast
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@en
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@nl
P2860
P921
P356
P1476
Cabazitaxel: a novel second-li ...... ion-resistant prostate cancer.
@en
P2093
Channing J Paller
Emmanuel S Antonarakis
P2860
P304
P356
10.2147/DDDT.S13029
P407
P577
2011-03-10T00:00:00Z